Skip to main content
Clinical Trials/NCT06467539
NCT06467539
Recruiting
Phase 2

Novel Augmentation of DAOIB and Antioxidant for Early Dementia

Chang Gung Memorial Hospital1 site in 1 country80 target enrollmentJune 19, 2024

Overview

Phase
Phase 2
Intervention
DAOIB plus AO
Conditions
Alzheimer Disease
Sponsor
Chang Gung Memorial Hospital
Enrollment
80
Locations
1
Primary Endpoint
Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

Previous studies found that some NMDA-enhancing agents were able to improve cognitive function of patients with early-phase dementia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of dementia too. Whether combined treatment of an NMDA-enhancing agent and a drug with antioxidant property can be better than an NMDA-enhancing agent alone deserves study.

Registry
clinicaltrials.gov
Start Date
June 19, 2024
End Date
May 2027
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Chang Gung Memorial Hospital
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Clinical diagnosis of Alzheimer's disease or mild cognitive impairment
  • MMSE between 10-26
  • CDR 1 or 0.5

Exclusion Criteria

  • Hachinski Ischemic Score \> 4
  • Substance abuse/dependence
  • Parkinson disease, epilepsy, dementia with psychotic features
  • Major depressive disorder
  • Major physical illnesses
  • Severe visual or hearing impairment

Arms & Interventions

Experimental

DAOIB plus Antioxidant agent (AO)

Intervention: DAOIB plus AO

Placebo Comparator

DAOIB plus Placebo

Intervention: DAOIB plus placebo

Outcomes

Primary Outcomes

Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24

Time Frame: week 0, 8, 16, 24

Alzheimer's disease assessment scale-cognitive subscale consists of 11 tasks. Its scores range from 0 (best) to 70 (worst).

Secondary Outcomes

  • Change from baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score at week 8, 16 and 24(week 0, 8, 16, 24)
  • Change from baseline in Alzheimer's disease Cooperative Study scale for ADL in MCI (ADCS-MCI-ADL) score at week 8, 16 and 24(week 0, 8, 16, 24)
  • Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input score at week 8, 16 and 24(week 8, 16, 24)
  • Change from baseline in Mini-Mental Status examination score at week 8, 16 and 24(week 0, 8, 16, 24)
  • Change from baseline in the composite score of a battery of additional cognitive tests at week 8, 16 and 24(week 0, 24)
  • Change from baseline in Medical Outcomes Study Short-Form-36 (SF-36) score at week 8, 16 and 24(week 0, 8, 16, 24)

Study Sites (1)

Loading locations...

Similar Trials